Etoricoxib Price Trend and Forecast 2026-2027

A gain of 7.2% in one quarter, that's how much Etoricoxib jumped in Q2 2026 alone, one of the sharper single-quarter moves we've tracked for this particular compound. Germany led the pack at a value of USD 76.85/KG, up from USD 71.70/KG in Q1. The container freight costs spiked hard during the quarter. The tight export allocations out of India compounded the squeeze even further. Globally the number is almost identical, from a value of USD 71.61/KG to USD 76.78/KG, also a gain of 7.2 percent. For the second half of 2026 (H2 2026), a range of USD 77-84/KG looks like the right one. That assumes the constrained API supply chains and the steady arthritis and pain management demand both hold.

Etoricoxib is a selective COX-2 inhibitor, built through a multi-step fluorination and cyclisation process starting from the pyridine and chlorobenzene intermediates. The selectivity matters clinically here. Targeting the COX-2 specifically, rather than both COX enzymes, cuts the inflammation and pain. It also spares much of the gastrointestinal side-effect burden that comes with the older, non-selective NSAIDs. Most of the demand traces back to the osteoarthritis and rheumatoid arthritis management, chronic conditions that don't go away when the supply tightens. The ankylosing spondylitis and acute gouty arthritis add a further slice. The post-operative pain management fills out the rest. The fluorination processing sets the cost baseline. The freight and CGMP audit expenses stack on top of that. The export allocation from the major supplying regions determines how tight things get in any given quarter.

Etoricoxib Price Forecast for 2026

A genuine supply strain, not a routine seasonal movement, that's the picture heading into the second half of 2026 (H2 2026). The formulators spent the H1 navigating the tight export allocations from Indian suppliers while the environmental inspections in China cut into the fluorination line output at the same time, an unusual double bind. The freight and insurance costs firmed sharply through the same period, keeping the production floor elevated across the board rather than in just one region.

If the export allocations tighten further, or more Chinese fluorination lines face environmental inspection shutdowns, the prices could push well past the band. A sharp easing in the freight costs, or new capacity coming online faster than expected, would work the other way around.

For the Quarter Ending June 2026

Etoricoxib Prices Q2 2026:

• United States: USD 76.77/KG
• China: USD 76.72/KG
• Germany: USD 76.85/KG
• India: USD 76.80/KG

Etoricoxib Prices in the United States

A jump of 7.2% took the US Etoricoxib from a value of USD 71.60/KG to USD 76.77/KG. The container freight was the main culprit here. The insurance costs on small-batch consignments spiked at the same time, and the tight Indian export allocations meant there wasn't much slack to absorb it.

Why did the price of Etoricoxib change in Q2 2026 in the United States?

Container freight and insurance costs rose sharply, and that alone drove most of the landed cost increase. Tight export allocation from Indian suppliers meant less prompt supply was available to soften the blow. Stringent CGMP audit fees and customs testing absorbed whatever freight savings there might otherwise have been, taking the market to USD 76.77/KG.

Etoricoxib Prices in China

China moved from a value of USD 71.54/KG to USD 76.72/KG, a rise of 7.2 percent nearly identical to the US move, but for a different reason. The environmental inspections cut into the fluorination line output at several eastern facilities during the quarter.

Why did the price of Etoricoxib change in Q2 2026 in China?

Environmental inspections reduced prompt availability across eastern Chinese fluorination lines, the dominant factor this quarter. Firm export enquiries and steady domestic demand added a secondary push. Pre-announced maintenance at a handful of facilities squeezed spot offers further.

Etoricoxib Prices in Germany

Germany topped every single tracked market at a value of USD 76.85/KG, up by 7.2% from Q1. The rising logistics costs across the constrained API supply chains explain most of it. The tighter regulatory compliance standards added a smaller but real contribution.

Why did the price of Etoricoxib change in Q2 2026 in Germany?

Rising logistics expenses and constrained API supply chains pushed production costs up meaningfully. Tighter regulatory compliance standards layered on top of that. Strong procurement demand from healthcare distributors sustained the climb through to USD 76.85/KG.

Etoricoxib Prices in India

India rose by 7.2% to a value of USD 76.80/KG, right in line with the other three regions. That itself says something important. A genuinely global supply squeeze, not just a regional quirk. The export allocation constraints kept the prompt availability tight throughout the quarter.

Why did the price of Etoricoxib change in Q2 2026 in India?

Export allocation constraints kept prompt availability tight across the major trade routes. Firm international demand from arthritis and pain management formulators added consistent pull. Fluorination processing costs contributed the final piece of upward pressure.

For the Quarter Ending March 2026

Etoricoxib Prices Q1 2026:

• United States: USD 71.60/KG
• China: USD 71.54/KG
• Germany: USD 71.70/KG
• India: USD 71.65/KG

Etoricoxib Prices in the United States

The US prices climbed by 3.7% to a value of USD 71.60/KG in Q1. The year-end buying cycles stayed subdued even so, with the wholesalers working through the existing inventory instead of placing fresh orders.

Why did the price of Etoricoxib change in Q1 2026 in the United States?

Constrained supply from tighter export allocations pushed landed costs higher despite the subdued buying mood. Stringent compliance and testing expenses absorbed most of any freight savings that came through. USD 71.60/KG is where things landed.

Etoricoxib Prices in China

China's Q1 average came to a value of USD 71.54/KG, up by 3.7% from Q4. The constrained supply and the steady export demand kept the enquiries firm all through the quarter. That set the stage for the much sharper move that followed in the Q2.

Why did the price of Etoricoxib change in Q1 2026 in China?

Constrained supply at fluorination facilities supported firmer pricing throughout the quarter. Steady domestic demand and firm export enquiries kept procurement active. That combination set the stage for the much stronger move in Q2.

Etoricoxib Prices in Germany

Germany rose by 3.7% to a value of USD 71.70/KG in Q1, driven by the increasing logistics expenses and the tighter regulatory compliance requirements, the same two factors that would intensify sharply by the Q2.

Why did the price of Etoricoxib change in Q1 2026 in Germany?

Increasing logistics expenses raised European production and distribution costs steadily through the quarter. Tighter regulatory compliance requirements added a further layer of pressure. USD 71.70/KG is where the quarter closed.

Etoricoxib Prices in India

India moved by 3.7% to a value of USD 71.65/KG, keeping pace almost exactly with the other three regions, a pattern that would repeat and intensify in the Q2. The tightening export allocation was already the main driver here.

Why did the price of Etoricoxib change in Q1 2026 in India?

Tightening export allocation constrained prompt availability through the quarter. Firm international demand from healthcare distributors kept procurement steady. The pattern set up the much sharper gain that followed in Q2.

Quarterly Etoricoxib Price Trends

Nothing like the previous five quarters, that's the last quarter of this entire six-quarter window. The global Etoricoxib prices climbed a steady 3.3-3.9 percent per quarter through Q1 2026, then suddenly jumped by 7.2% in Q2, roughly double the prior pace. From a value of USD 62.05/KG in Q1 2025 to USD 76.78/KG by Q2 2026, a cumulative gain of 23.7 percent. The constrained API supply chains and a sharp rise in the logistics costs explain the acceleration.

What was Etoricoxib Price in 2025?

Steady, unremarkable growth, that was the year 2025 for Etoricoxib, at least by the standards of what came after it. The global average opened at a value of USD 62.05/KG in Q1, closed at USD 69.07/KG in Q4, a gain of 11.3 percent across the year. The constrained API supply chains, the tightening regulatory compliance standards, and the strong healthcare procurement demand, all drove the increase. None of it carried the kind of sharp single-quarter spike that would show up in early 2026.

Etoricoxib Prices in the United States in 2025

The US prices rose by 11.3% over the year, from a value of USD 62.05/KG to USD 69.05/KG. The rising logistics expenses, along with the tightening compliance requirements, were the consistent drivers throughout.

Etoricoxib Prices in China in 2025

China matched the pattern almost exactly, up by 11.3 percent, from a value of USD 62.00/KG to USD 69.00/KG. The constrained fluorination capacity, along with the steady export demand, kept the increase on track quarter after quarter.

Etoricoxib Prices in Germany in 2025

Germany posted the largest gain of all four regions at 11.4 percent, from a value of USD 62.10/KG to USD 69.15/KG. The rising logistics costs, along with the tightening compliance standards, were the main factors.

Etoricoxib Prices in India in 2025

India rose by 11.3 percent, from a value of USD 62.08/KG to USD 69.10/KG, essentially tracking the other three regions in lockstep. The tightening export allocation constraints were the recurring theme here.

How We Can Help

Expert Market Research: Your Source for Real-Time Etoricoxib Price Intelligence

Expert Market Research tracks the Etoricoxib prices continuously, across every major producing and consuming region. The team traces the causation through the fluorination processing economics, the container freight and compliance cost cycles, and the shifting arthritis and pain management demand. Contact Expert Market Research today for the Etoricoxib pricing data, a bespoke market analysis, and a strategic procurement advisory.